Eledon Pharmaceuticals Inc

ELDN.US
Healthcare · Biotechnology
3.40
-0.17 (-4.76%)
USD · NASDAQ

Company Information

Company Name
Eledon Pharmaceuticals Inc
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
ISIN: US28617K1016
CIK: 0001404281
CUSIP: 28617K101
Currency: USD
Full Time Employees: 33
Phone: 949 238 8090
Fiscal Year End: December
IPO Date: Sep 17, 2014
Description:

Eledon Pharmaceuticals, Inc. operates as a clinical stage biotechnology company. It uses its immunology expertise in targeting the CD40 Ligand (CD40L) pathway to develop therapies to protect transplanted organs and prevent rejection, and to treat amyotrophic lateral sclerosis (ALS). The company's lead compound in development is tegoprubart, an IgG1 and anti-CD40L antibody with high affinity for CD40 Ligand, a biological target with therapeutic potential. It is also developing its products for the prevention of allograft rejection in kidney transplantation and xenotransplantation. The company has a collaboration agreement with eGenesis, Inc.; and a strategic collaboration with NewcelX Ltd. for the development of the NCEL-101 therapy for Type 1 Diabetes. The company was formerly known as Novus Therapeutics, Inc. and changed its name to Eledon Pharmaceuticals, Inc. in January 2021. Eledon Pharmaceuticals, Inc. is headquartered in Irvine, California.

Address:

19800 MacArthur Boulevard, Irvine, CA, United States, 92612

People

Directors & Officers

Name Title Year Born
Dr. David-Alexandre C. Gros M.D., Ph.D. CEO & Non Independent Director 1972
Dr. Steven N. Perrin Ph.D. President, Chief Scientific Officer & Non Independent Director 1966
Mr. Paul Sean Little Chief Financial Officer 1965
Mr. John Herberger Vice President of Technical Operations NA
Mr. Bryan E. Smith J.D. General Counsel, Corporate Secretary & Chief Compliance Officer 1980
Dr. David Hovland Ph.D. Chief Regulatory Officer NA
Ms. Marina Escudero VP & Head of Clinical Operations NA

Insider Trading

Date Insider Name Title Transaction Type Shares Price Value
Dec 20, 2021 David-Alexandre C Gros N/A Purchase 2.00K $4.48 $8.96K

Shareholders

Institutional Holders

Holder Name Shares Date Reported % Out Value % Change
Bvf Inc 6.29M Mar 31, 2026 8.15% $0.62 0.00%
BlackRock Inc 4.38M Mar 31, 2026 5.68% $0.00 20.82%
Vanguard Group Inc 4.04M Dec 31, 2025 5.23% $0.00 23.62%
Defilade Capital Management, L.P. 3.56M Mar 31, 2026 4.62% $1.54 8.32%
Vanguard Capital Management, LLC 3.29M Mar 31, 2026 4.27% $0.00 0.00%
Ensign Peak Advisors Inc 2.46M Mar 31, 2026 3.19% $0.01 0.00%
Zimmer Partners LP 1.88M Mar 31, 2026 2.43% $0.14 -21.36%
Geode Capital Management, LLC 1.79M Mar 31, 2026 2.32% $0.00 26.04%
Sphera Funds Management Ltd. 1.77M Mar 31, 2026 2.30% $0.87 -16.88%
Catalio Capital Management, LP 1.64M Mar 31, 2026 2.12% $1.06 30.16%
Blue Owl Capital Holdings LP 1.42M Mar 31, 2026 1.84% $1.18 -26.43%
State Street Corp 1.15M Mar 31, 2026 1.50% $0.00 49.20%
Awm Investment Company Inc 1.10M Mar 31, 2026 1.43% $0.38 0.00%
Jefferies Financial Group Inc 1.09M Mar 31, 2026 1.42% $0.02 -30.76%
Kingdon Capital Management LLC 1.04M Mar 31, 2026 1.35% $0.35 0.00%
ADAR1 Capital Management LLC 974.42K Mar 31, 2026 1.26% $0.18 -46.51%
Bank of America Corp 869.54K Mar 31, 2026 1.13% $0.00 1,346.88%
Sanofi 814.98K Mar 31, 2026 1.06% $0.75 0.00%
CM Management, LLC 650.00K Mar 31, 2026 0.84% $1.67 0.00%
22NW, LP 636.36K Mar 31, 2026 0.82% $1.34 0.00%

Fund Holdings

Rank Holder Name Shares Held % of Shares Change Date Reported
1 Vanguard Total Stock Mkt Idx Inv 2.48M 3.22% ▲ 5.39% Jun 30, 2026
2 iShares Russell 2000 ETF 2.05M 2.66% ▲ 0.60% Jun 30, 2026
3 Vanguard Institutional Extnd Mkt Idx Tr 854.63K 1.11% ▲ 0.00% Jun 30, 2026
4 Fidelity Small Cap Index 740.03K 0.96% ▲ 1.26% Apr 30, 2026
5 iShares Russell 2000 Growth ETF 720.64K 0.93% ▼ 0.38% Jun 30, 2026
6 State St Russell Sm/Mid Cp® Indx SL Cl I 497.55K 0.64% ▲ 150.47% Jun 30, 2026
7 Russell 2000 Index Non-Lendable Fund 487.07K 0.63% ▼ 0.15% Jun 30, 2026
8 Russell 2000 Equity Index Fund B 487.07K 0.63% ▼ 0.15% Jun 30, 2026
9 Vanguard Russell 2000 ETF 442.87K 0.57% ▲ 15.34% Jun 30, 2026
10 Fidelity Extended Market Index 389.37K 0.50% ▼ 5.29% May 31, 2026

Financial Highlights

Market Cap: $276.33M
EBITDA: $-36.86M
Book Value: $1.32
Earnings/Share: $-0.77
Profit Margin: 0.00%
Operating Margin: 0.00%
ROA (TTM): -35.10%
ROE (TTM): -72.68%
Revenue (TTM): $0.00
Revenue/Share (TTM): $0.00
Earnings Growth (YOY): 0.00%
Revenue Growth (YOY): 0.00%

Valuation Metrics

Enterprise Value: $165.03M
Trailing P/E: 0.00
Forward P/E: 5.39

Shares Statistics

Shares Outstanding: 77.19M
Shares Float: 69.93M
% Insiders: 109.20%
% Institutions: 5,985.10%
Short % Float: 7.16%

Stock Price History

1 Year Price History

2 Years Price History

5 Years Price History

10 Years Price History

Financial Charts

Revenue & Net Income (Yearly)

Revenue & Net Income (Quarterly)

Operating Expenses (Yearly)

Operating Expenses (Quarterly)

Balance Sheet (Quarterly)

Assets Breakdown (Yearly)

Assets Breakdown (Quarterly)

Liabilities Breakdown (Yearly)

Liabilities Breakdown (Quarterly)

Income Statement Waterfall

Open full waterfall
Line Item
Step Type
Value
Revenue
adjust
$0.00
Gross Profit
subtotal
$0.00
SG&A
adjust
$-16.98M
R&D
adjust
$-66.27M
Operating Income
subtotal
$-83.25M
Other / Non-Operating Items
adjust
$37.63M
Net Income
subtotal
$-45.62M

Earnings Per Share (EPS) History

Financial Ratios

📦 Raw API Data (JSON Explorer)

Watchlist

0

No stocks in watchlist

Assistant

×
Hello! I'm your AI assistant. I have access to the financial data on this page. Ask me anything about ELDN.US!